Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
Human papillomavirus (HPV)
Measles
English (EN)
SAGE documentation
2017
Evidence to recommendation table
Clear all
Type of publications
SAGE documentation
(5)
Topics
Evidence to recommendation table
(5)
Available to download in languages
English (EN)
(5)
Regions
Countries
Diseases
Human papillomavirus (HPV)
(3)
Measles
(2)
Diphtheria
(1)
Hepatitis B
(2)
Pneumococcal disease
(2)
Rabies
(2)
Typhoid
(1)
Vaccine topics
Target population
Publication date
2017
(5)
5 results found
2017
∙
SAGE
Should SAGE recommend the removal of the criterion that MCV2 only be given if MCV1 coverage is >80% for the introduction of routine measles second dose as stated in the 2009 measles vaccine position paper?
2017
∙
SAGE
Should HIV-infected children receiving highly active antiretroviral therapy be revaccinated against measles?
2017
∙
SAGE
In 9 to 15-year old females, is 9-valent human papillomavirus vaccine (HPV) vaccine superior to 4-valent or 2-valent HPV vaccines?
2017
∙
SAGE
What is the incremental effectiveness and cost-effectiveness of vaccinating multiple age cohorts versus a single age cohort in high income countries (HIC) and low and middle income countries (LMIC)?
2017
∙
SAGE
What is the public health impact on cervical cancer of administering HPV vaccine to 9 to 15-year old females and males versus to 9 to 15-year old females?
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register